<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33826063</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-4978</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>3</Issue><PubDate><Year>2021</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Molecular biology reports</Title><ISOAbbreviation>Mol Biol Rep</ISOAbbreviation></Journal><ArticleTitle>Lack of association between TREM2 rs75932628 variant and amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>2601</StartPage><EndPage>2610</EndPage><MedlinePgn>2601-2610</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11033-021-06312-1</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a multifactorial neurodegenerative disease. Inflammatory processes are among the mechanisms that are implicated in ALS pathogenesis. The TREM2 rs75932628 T variant may influence the regulatory effect of TREM2 on inflammation. Studies regarding the role of the rs75932628 variant in ALS have yielded inconsistent results, so far. To assess the role of TREM2 rs75932628 on ALS risk. We genotyped 155 patients with sporadic ALS and 155 healthy controls for TREM2 rs75932628. We also merged and meta-analyzed our data with data from previous studies (with a total of 7524 ALS cases and 14,675 controls), regarding TREM2 rs75932628 and ALS. No ALS or healthy subjects carried the TREM2 rs75932628-T variant. Results from meta-analyses (overall approach and sensitivity analyses) yielded no significant results for possible connection between TREM2 rs75932628-T variant and ALS. Based on our results, TREM2 rs75932628 does not seem to play a determining role to the pathophysiology of ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Siokas</LastName><ForeName>Vasileios</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Aloizou</LastName><ForeName>Athina-Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liampas</LastName><ForeName>Ioannis</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsouris</LastName><ForeName>Zisis</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mentis</LastName><ForeName>Alexios-Fotios A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Public Health Laboratories, Hellenic Pasteur Institute, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nasios</LastName><ForeName>Grigorios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Speech and Language Therapy, University of Ioannina, Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadimitriou</LastName><ForeName>Dimitra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurological Department, Henry Dunant Hospital Center, 11526, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogdanos</LastName><ForeName>Dimitrios P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hadjigeorgiou</LastName><ForeName>Georgios M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dardiotis</LastName><ForeName>Efthimios</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2957-641X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Laboratory of Neurogenetics, University Hospital of Larissa, Larissa, Greece. edar@med.uth.gr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Mezourlo Hill, 41100, Larissa, Greece. edar@med.uth.gr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>code: 5287</GrantID><Agency>This study was supported in part by a research grant from the Research Committee of the University of Thessaly, Greece (code: 5287).</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mol Biol Rep</MedlineTA><NlmUniqueID>0403234</NlmUniqueID><ISSNLinking>0301-4851</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C498715">TREM2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="Y">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017594" MajorTopicYN="N">Publication Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Genetic variant</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">TREM2</Keyword><Keyword MajorTopicYN="N">rs75932628</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33826063</ArticleId><ArticleId IdType="doi">10.1007/s11033-021-06312-1</ArticleId><ArticleId IdType="pii">10.1007/s11033-021-06312-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Picher-Martel V, Valdmanis PN, Gould PV, Julien JP, Dupr&#xe9; N (2016) From animal models to human disease: a genetic approach for personalized medicine in ALS. Acta Neuropathol Commun 4(1):70. https://doi.org/10.1186/s40478-016-0340-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0340-5</ArticleId><ArticleId IdType="pubmed">27400686</ArticleId><ArticleId IdType="pmc">4940869</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9(11):617&#x2013;628. https://doi.org/10.1038/nrneurol.2013.203</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2013.203</ArticleId><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH (2017) Amyotrophic lateral sclerosis. Lancet 390(10107):2084&#x2013;2098. https://doi.org/10.1016/S0140-6736(17)31287-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Swinnen B, Robberecht W (2014) The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 10(11):661&#x2013;670. https://doi.org/10.1038/nrneurol.2014.184</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.184</ArticleId><ArticleId IdType="pubmed">25311585</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Alberici A, Cairns NJ, Romano M, Buratti E (2020) From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline. Mol Neurodegener 15(1):31. https://doi.org/10.1186/s13024-020-00373-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00373-9</ArticleId><ArticleId IdType="pubmed">32487123</ArticleId><ArticleId IdType="pmc">7268618</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S (2019) Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci 20(11):2818. https://doi.org/10.3390/ijms20112818</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms20112818</ArticleId><ArticleId IdType="pmc">6600525</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Aloizou AM, Siokas V, Patrinos GP, Deretzi G, Mitsias P, Aschner M, Tsatsakis A (2018) The role of microRNAs in patients with amyotrophic lateral sclerosis. J Mol Neurosci 66(4):617&#x2013;628. https://doi.org/10.1007/s12031-018-1204-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-018-1204-1</ArticleId><ArticleId IdType="pubmed">30415446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett SA, Tanaz R, Cobos SN, Torrente MP (2019) Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease. Transl Res 204:19&#x2013;30. https://doi.org/10.1016/j.trsl.2018.10.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2018.10.002</ArticleId><ArticleId IdType="pubmed">30391475</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor JP, Brown RH Jr, Cleveland DW (2016) Decoding ALS: from genes to mechanism. Nature 539(7628):197&#x2013;206. https://doi.org/10.1038/nature20413</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20413</ArticleId><ArticleId IdType="pubmed">27830784</ArticleId><ArticleId IdType="pmc">5585017</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377(2):162&#x2013;172. https://doi.org/10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Lewis CM (2011) Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 71(4):281&#x2013;288. https://doi.org/10.1159/000330167</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000330167</ArticleId><ArticleId IdType="pubmed">21846995</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, van der Spek RA, V&#xf5;sa U, de Jong S, Robinson MR, Yang J, Fogh I, van Doormaal PT, Tazelaar GH, Koppers M, Blokhuis AM, Sproviero W, Jones AR, Kenna KP, van Eijk KR, Harschnitz O, Schellevis RD, Brands WJ, Medic J, Menelaou A, Vajda A, Ticozzi N, Lin K, Rogelj B, Vrabec K, Ravnik-Glava&#x10d; M, Koritnik B, Zidar J, Leonardis L, Gro&#x161;elj LD, Millecamps S, Salachas F, Meininger V, de Carvalho M, Pinto S, Mora JS, Rojas-Garc&#xed;a R, Polak M, Chandran S, Colville S, Swingler R, Morrison KE, Shaw PJ, Hardy J, Orrell RW, Pittman A, Sidle K, Fratta P, Malaspina A, Topp S, Petri S, Abdulla S, Drepper C, Sendtner M, Meyer T, Ophoff RA, Staats KA, Wiedau-Pazos M, Lomen-Hoerth C, Van Deerlin VM, Trojanowski JQ, Elman L, McCluskey L, Basak AN, Tunca C, Hamzeiy H, Parman Y, Meitinger T, Lichtner P, Radivojkov-Blagojevic M, Andres CR, Maurel C, Bensimon G, Landwehrmeyer B, Brice A, Payan CA, Saker-Delye S, D&#xfc;rr A, Wood NW, Tittmann L, Lieb W, Franke A, Rietschel M, Cichon S, N&#xf6;then MM, Amouyel P, Tzourio C, Dartigues JF, Uitterlinden AG, Rivadeneira F, Estrada K, Hofman A, Curtis C, Blauw HM, van der Kooi AJ, de Visser M, Goris A, Weber M, Shaw CE, Smith BN, Pansarasa O, Cereda C, Del Bo R, Comi GP, D&#x2019;Alfonso S, Bertolin C, Sorar&#xf9; G, Mazzini L, Pensato V, Gellera C, Tiloca C, Ratti A, Calvo A, Moglia C, Brunetti M, Arcuti S, Capozzo R, Zecca C, Lunetta C, Penco S, Riva N, Padovani A, Filosto M, Muller B, Stuit RJ, Blair I, Zhang K, McCann EP, Fifita JA, Nicholson GA, Rowe DB, Pamphlett R, Kiernan MC, Grosskreutz J, Witte OW, Ringer T, Prell T, Stubendorff B, Kurth I, H&#xfc;bner CA, Leigh PN, Casale F, Chio A, Beghi E, Pupillo E, Tortelli R, Logroscino G, Powell J, Ludolph AC, Weishaupt JH, Robberecht W, Van Damme P, Franke L, Pers TH, Brown RH, Glass JD, Landers JE, Hardiman O, Andersen PM, Corcia P, Vourc&#x2019;h P, Silani V, Wray NR, Visscher PM, de Bakker PI, van Es MA, Pasterkamp RJ, Lewis CM, Breen G, Al-Chalabi A, van den Berg LH, Veldink JH (2016) Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet 48(9):1043&#x2013;1048. https://doi.org/10.1038/ng.3622</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.3622</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId><ArticleId IdType="pmc">5556360</ArticleId></ArticleIdList></Reference><Reference><Citation>Klesney-Tait J, Turnbull IR, Colonna M (2006) The TREM receptor family and signal integration. Nat Immunol 7(12):1266&#x2013;1273. https://doi.org/10.1038/ni1411</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1411</ArticleId><ArticleId IdType="pubmed">17110943</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulland TK, Colonna M (2018) TREM2&#x2014;a key player in microglial biology and Alzheimer disease. Nat Rev Neurol 14(11):667&#x2013;675. https://doi.org/10.1038/s41582-018-0072-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0072-1</ArticleId><ArticleId IdType="pubmed">30266932</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Chen X-F (2019) The emerging roles and therapeutic potential of soluble TREM2 in Alzheimer&#x2019;s disease. Front Aging Neurosci 11:328&#x2013;328. https://doi.org/10.3389/fnagi.2019.00328</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00328</ArticleId><ArticleId IdType="pubmed">32038221</ArticleId><ArticleId IdType="pmc">6988790</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Z, Zhang X, Dong W, Wang X, He S, Zhang H, Wang X, Wei R, Chen Y, Liu X, Guo C (2020) TREM2 suppresses the proinflammatory response to facilitate PRRSV infection via PI3K/NF-&#x3ba;B signaling. PLoS Pathog 16(5):e1008543&#x2013;e1008543. https://doi.org/10.1371/journal.ppat.1008543</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1008543</ArticleId><ArticleId IdType="pubmed">32401783</ArticleId><ArticleId IdType="pmc">7250469</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Siokas V, Pantazi E, Dardioti M, Rikos D, Xiromerisiou G, Markou A, Papadimitriou D, Speletas M, Hadjigeorgiou GM (2017) A novel mutation in TREM2 gene causing Nasu-Hakola disease and review of the literature. Neurobiol Aging 53:194.e113-194.e122. https://doi.org/10.1016/j.neurobiolaging.2017.01.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2017.01.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, Kertesz A, Bigio EH, Lippa C, Josephs KA, Knopman DS, White CL, Caselli R, Mackenzie IR, Miller BL, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, Barcikowska M, Younkin SG, Petersen RC, Ertekin-Taner N, Uitti RJ, Meschia JF, Boylan KB, Boeve BF, Graff-Radford NR, Wszolek ZK, Dickson DW, Rademakers R, Ross OA (2013) TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson&#x2019;s disease. Mol Neurodegener 8(1):19. https://doi.org/10.1186/1750-1326-8-19</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-8-19</ArticleId><ArticleId IdType="pubmed">23800361</ArticleId><ArticleId IdType="pmc">3691612</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerreiro R, Hardy J (2013) TREM2 and neurodegenerative disease. N Engl J Med 369(16):1569&#x2013;1570. https://doi.org/10.1056/NEJMc1306509</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1306509</ArticleId><ArticleId IdType="pubmed">24143816</ArticleId></ArticleIdList></Reference><Reference><Citation>Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A, Stefansson K (2013) Variant of TREM2 associated with the risk of Alzheimer&#x2019;s disease. N Engl J Med 368(2):107&#x2013;116. https://doi.org/10.1056/NEJMoa1211103</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1211103</ArticleId><ArticleId IdType="pubmed">23150908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou SL, Tan CC, Hou XH, Cao XP, Tan L, Yu JT (2019) TREM2 variants and neurodegenerative diseases: a systematic review and meta-analysis. J Alzheimer&#x2019;s Dis 68(3):1171&#x2013;1184. https://doi.org/10.3233/jad-181038</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-181038</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, Nakano I, Ravits J, Robberecht W, Shefner J (2015) A revision of the El Escorial criteria&#x2014;2015. Amyotroph Lateral Scler Frontotemp Degener 16(5&#x2013;6):291&#x2013;292. https://doi.org/10.3109/21678421.2015.1049183</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1049183</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Karampinis E, Siokas V, Aloizou AM, Rikos D, Ralli S, Papadimitriou D, Bogdanos DP, Hadjigeorgiou GM (2019) ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population. Neurol Sci 40(6):1237&#x2013;1244. https://doi.org/10.1007/s10072-019-03825-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-019-03825-3</ArticleId><ArticleId IdType="pubmed">30879219</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V, Karampinis E, Aloizou AM, Mentis AA, Liakos P, Papadimitriou D, Liampas I, Nasios G, Bogdanos DP, Hadjigeorgiou GM, Dardiotis E (2020) CYP1A2 rs762551 polymorphism and risk for amyotrophic lateral sclerosis. Neurol Sci. https://doi.org/10.1007/s10072-020-04535-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04535-x</ArticleId><ArticleId IdType="pubmed">32592103</ArticleId></ArticleIdList></Reference><Reference><Citation>Siokas V, Kardaras D, Aloizou AM, Asproudis I, Boboridis KG, Papageorgiou E, Hadjigeorgiou GM, Tsironi EE, Dardiotis E (2019) BDNF rs6265 (Val66Met) polymorphism as a risk factor for blepharospasm. Neuro Mol Med 21(1):68&#x2013;74. https://doi.org/10.1007/s12017-018-8519-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12017-018-8519-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Liberati A, Altman DG, Tetzlaff J, Mulrow C, G&#xf8;tzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. https://doi.org/10.1136/bmj.b2700</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2700</ArticleId><ArticleId IdType="pubmed">2714672</ArticleId><ArticleId IdType="pmc">2714672</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke NE, Clements AC, Doi SA, Wang D, Campbell SJ, Gray D, Nery SV (2017) Differential effect of mass deworming and targeted deworming for soil-transmitted helminth control in children: a systematic review and meta-analysis. Lancet 389(10066):287&#x2013;297. https://doi.org/10.1016/s0140-6736(16)32123-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(16)32123-7</ArticleId><ArticleId IdType="pubmed">27979381</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101&#x2013;129. https://doi.org/10.2307/3001666</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/3001666</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557&#x2013;560. https://doi.org/10.1136/bmj.327.7414.557</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId><ArticleId IdType="pubmed">12958120</ArticleId><ArticleId IdType="pmc">192859</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177&#x2013;188. https://doi.org/10.1016/0197-2456(86)90046-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-2456(86)90046-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. JNCI 22(4):719&#x2013;748. https://doi.org/10.1093/jnci/22.4.719</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnci/22.4.719</ArticleId><ArticleId IdType="pubmed">13655060</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee I (2009) CD14 C260T promoter polymorphism and the risk of cerebrovascular diseases: a meta-analysis. J Appl Genet 50(2):153&#x2013;157. https://doi.org/10.1007/BF03195667</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03195667</ArticleId><ArticleId IdType="pubmed">19433913</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya-Kanamori L, Barendregt JJ, Doi SAR (2018) A new improved graphical and quantitative method for detecting bias in meta-analysis. Int J Evid-Based Healthc 16(4):195&#x2013;203. https://doi.org/10.1097/xeb.0000000000000141</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/xeb.0000000000000141</ArticleId><ArticleId IdType="pubmed">29621038</ArticleId></ArticleIdList></Reference><Reference><Citation>Efthimiou O (2018) Practical guide to the meta-analysis of rare events. Evid Based Ment Health 21(2):72&#x2013;76. https://doi.org/10.1136/eb-2018-102911</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/eb-2018-102911</ArticleId><ArticleId IdType="pubmed">29650528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayer AH, Wojta K, Ramos EM, Dokuru D, Chen JA, Karydas AM, Papatriantafyllou JD, Agiomyrgiannakis D, Kamtsadeli V, Tsinia N, Sali D, Gylys KH, Agosta F, Filippi M, Small GW, Bennett DA, Gearing M, Juncos JL, Kramer J, Lee SE, Yokoyama JS, Mendez MF, Chui H, Zarow C, Ringman JM, Kilic U, Babacan-Yildiz G, Levey A, DeCarli CS, Cotman CW, Boxer AL, Miller BL, Coppola G (2019) Frequency of the TREM2 R47H variant in various neurodegenerative disorders. Alzheimer Dis Assoc Disord 33(4):327&#x2013;330. https://doi.org/10.1097/wad.0000000000000339</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wad.0000000000000339</ArticleId><ArticleId IdType="pubmed">31513029</ArticleId><ArticleId IdType="pmc">7050643</ArticleId></ArticleIdList></Reference><Reference><Citation>Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P, Baloh RH, Ravits J, Simpson E, Appel SH, Pestronk A, Goate AM, Miller TM, Cruchaga C, Harms MB (2014) TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71(4):449&#x2013;453. https://doi.org/10.1001/jamaneurol.2013.6237</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2013.6237</ArticleId><ArticleId IdType="pubmed">24535663</ArticleId><ArticleId IdType="pmc">4087113</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Chen Y, Wei Q, Guo X, Cao B, Ou R, Zhao B, Shang HF (2015) Assessment of TREM2 rs75932628 association with amyotrophic lateral sclerosis in a Chinese population. J Neurol Sci 355(1&#x2013;2):193&#x2013;195. https://doi.org/10.1016/j.jns.2015.05.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.05.010</ArticleId><ArticleId IdType="pubmed">26026943</ArticleId></ArticleIdList></Reference><Reference><Citation>Lill CM, Rengmark A, Pihlstr&#xf8;m L, Fogh I, Shatunov A, Sleiman PM, Wang LS, Liu T, Lassen CF, Meissner E, Alexopoulos P, Calvo A, Chio A, Dizdar N, Faltraco F, Forsgren L, Kirchheiner J, Kurz A, Larsen JP, Liebsch M, Linder J, Morrison KE, Nissbrandt H, Otto M, Pahnke J, Partch A, Restagno G, Rujescu D, Schnack C, Shaw CE, Shaw PJ, Tumani H, Tysnes OB, Valladares O, Silani V, van den Berg LH, van Rheenen W, Veldink JH, Lindenberger U, Steinhagen-Thiessen E, Teipel S, Perneczky R, Hakonarson H, Hampel H, von Arnim CAF, Olsen JH, Van Deerlin VM, Al-Chalabi A, Toft M, Ritz B, Bertram L (2015) The role of TREM2 R47H as a risk factor for Alzheimer&#x2019;s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson&#x2019;s disease. Alzheimer&#x2019;s Dement 11(12):1407&#x2013;1416. https://doi.org/10.1016/j.jalz.2014.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2014.12.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Peplonska B, Berdynski M, Mandecka M, Barczak A, Kuzma-Kozakiewicz M, Barcikowska M, Zekanowski C (2018) TREM2 variants in neurodegenerative disorders in the polish population. Homozygosity and compound heterozygosity in FTD patients. Amyotroph Later Scler Frontotemp Degener 19(5&#x2013;6):407&#x2013;412. https://doi.org/10.1080/21678421.2018.1451894</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1451894</ArticleId></ArticleIdList></Reference><Reference><Citation>Rikos D, Siokas V, Aloizou AM, Tsouris Z, Aslanidou P, Koutsis G, Anagnostouli M, Bogdanos DP, Grigoriadis N, Hadjigeorgiou GM, Dardiotis E (2019) TREM2 R47H (rs75932628) variant is unlikely to contribute to multiple sclerosis susceptibility and severity in a large Greek MS cohort. Mult Scler Relat Disord 35:116&#x2013;118. https://doi.org/10.1016/j.msard.2019.07.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2019.07.007</ArticleId><ArticleId IdType="pubmed">31362167</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29(1):308&#x2013;311. https://doi.org/10.1093/nar/29.1.308</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/29.1.308</ArticleId><ArticleId IdType="pubmed">11125122</ArticleId><ArticleId IdType="pmc">29783</ArticleId></ArticleIdList></Reference><Reference><Citation>Dardiotis E, Rikos D, Siokas V, Aloizou AM, Tsouris Z, Sakalakis E, Brotis AG, Bogdanos DP, Hadjigeorgiou GM (2020) Assessment of TREM2 rs75932628 variant&#x2019;s association with Parkinson&#x2019;s disease in a Greek population and meta-analysis of current data. Int J Neurosci. https://doi.org/10.1080/00207454.2020.1750388</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00207454.2020.1750388</ArticleId><ArticleId IdType="pubmed">32250197</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Cubero S, Lorenzo-Betancor O, Lorenzo E, Ag&#xfa;ndez JA, Jim&#xe9;nez-Jim&#xe9;nez FJ, Ross OA, Wurster I, Mielke C, Lin JJ, Coria F, Clarimon J, Ezquerra M, Brighina L, Annesi G, Alonso-Navarro H, Garc&#xed;a-Martin E, Gironell A, Marti MJ, Yueh KC, Wszolek ZK, Sharma M, Berg D, Kr&#xfc;ger R, Pastor MA, Pastor P (2015) TREM2 R47H variant and risk of essential tremor: a cross-sectional international multicenter study. Parkinsonism Relat Disord 21(3):306&#x2013;309. https://doi.org/10.1016/j.parkreldis.2014.12.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2014.12.010</ArticleId><ArticleId IdType="pubmed">25585992</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Morenas-Rodr&#xed;guez E, Kleinberger G, Schlepckow K, Araque Caballero M&#xc1;, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, Levin J, Deming Y, Piccio L, Karch CM, Cruchaga C, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C, for the Alzheimer&#x2019;s Disease Neuroimaging I (2019) Early increase of CSF sTREM2 in Alzheimer&#x2019;s disease is associated with tau related-neurodegeneration but not with amyloid-&#x3b2; pathology. Mol Neurodegener 14(1):1. https://doi.org/10.1186/s13024-018-0301-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0301-5</ArticleId><ArticleId IdType="pubmed">30630532</ArticleId><ArticleId IdType="pmc">6327425</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X, Chen K, Wang N, Zhu L, Can D, Marten Y, Shinohara M, Liu CC, Du D, Sun H, Wen L, Xu H, Bu G, Chen XF (2019) Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions in an Alzheimer&#x2019;s disease model. Nat Commun 10(1):1365. https://doi.org/10.1038/s41467-019-09118-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-09118-9</ArticleId><ArticleId IdType="pubmed">30911003</ArticleId><ArticleId IdType="pmc">6433910</ArticleId></ArticleIdList></Reference><Reference><Citation>Su&#xe1;rez-Calvet M, Kleinberger G, Araque Caballero M, Brendel M, Rominger A, Alcolea D, Fortea J, Lle&#xf3; A, Blesa R, Gispert JD, S&#xe1;nchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Trasch&#xfc;tz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellg&#xe5;rd B, Blennow K, Crispin A, Ewers M, Haass C (2016) sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer&#x2019;s disease and associate with neuronal injury markers. EMBO Mol Med 8(5):466&#x2013;476. https://doi.org/10.15252/emmm.201506123</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201506123</ArticleId><ArticleId IdType="pubmed">26941262</ArticleId><ArticleId IdType="pmc">5120370</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper-Knock J, Green C, Altschuler G, Wei W, Bury JJ, Heath PR, Wyles M, Gelsthorpe C, Highley JR, Lorente-Pons A, Beck T, Doyle K, Otero K, Traynor B, Kirby J, Shaw PJ, Hide W (2017) A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis. Acta Neuropathol Commun 5(1):23. https://doi.org/10.1186/s40478-017-0424-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-017-0424-x</ArticleId><ArticleId IdType="pubmed">28302159</ArticleId><ArticleId IdType="pmc">5353945</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, Glass JD, Brown RH Jr, Ladha SS, Lacomis D, Harris JM, Scearce-Levie K, Ho C, Bowser R, Berry JD (2020) Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 7(7):1103&#x2013;1116. https://doi.org/10.1002/acn3.51078</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51078</ArticleId><ArticleId IdType="pubmed">32515902</ArticleId><ArticleId IdType="pmc">7359115</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T, Al Khleifat A, Meurgey J-H, Jones A, Leigh PN, Bensimon G, Al-Chalabi A (2018) Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. Lancet Neurol 17(5):416&#x2013;422. https://doi.org/10.1016/S1474-4422(18)30054-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30054-1</ArticleId><ArticleId IdType="pubmed">29525492</ArticleId><ArticleId IdType="pmc">5899963</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B, Wu Y, Wang Y, Yang H, Du B, Di W, Xu X, Shi X (2020) Cerebrospinal fluid MFG-E8 as a promising biomarker of amyotrophic lateral sclerosis. Neurol Sci. https://doi.org/10.1007/s10072-020-04416-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04416-3</ArticleId><ArticleId IdType="pubmed">33247320</ArticleId><ArticleId IdType="pmc">7324486</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>